RS67362B1 - Supstituisana piridopirimidinonil jedinjenja korisna kao aktivatori t ćelija - Google Patents
Supstituisana piridopirimidinonil jedinjenja korisna kao aktivatori t ćelijaInfo
- Publication number
- RS67362B1 RS67362B1 RS20251083A RSP20251083A RS67362B1 RS 67362 B1 RS67362 B1 RS 67362B1 RS 20251083 A RS20251083 A RS 20251083A RS P20251083 A RSP20251083 A RS P20251083A RS 67362 B1 RS67362 B1 RS 67362B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- oxo
- dihydropyrido
- carbonitrile
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892799P | 2019-08-28 | 2019-08-28 | |
| PCT/US2020/048070 WO2021041588A1 (en) | 2019-08-28 | 2020-08-27 | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
| EP20768221.2A EP4021901B1 (en) | 2019-08-28 | 2020-08-27 | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67362B1 true RS67362B1 (sr) | 2025-11-28 |
Family
ID=72422304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20251083A RS67362B1 (sr) | 2019-08-28 | 2020-08-27 | Supstituisana piridopirimidinonil jedinjenja korisna kao aktivatori t ćelija |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11584747B2 (enExample) |
| EP (1) | EP4021901B1 (enExample) |
| JP (1) | JP7650864B2 (enExample) |
| KR (1) | KR102980691B1 (enExample) |
| CN (1) | CN114302884B (enExample) |
| AR (1) | AR119821A1 (enExample) |
| AU (1) | AU2020336089C1 (enExample) |
| BR (1) | BR112022001862A2 (enExample) |
| CA (1) | CA3149594A1 (enExample) |
| CL (1) | CL2022000485A1 (enExample) |
| CO (1) | CO2022002424A2 (enExample) |
| DK (1) | DK4021901T3 (enExample) |
| ES (1) | ES3057035T3 (enExample) |
| FI (1) | FI4021901T3 (enExample) |
| HR (1) | HRP20251203T1 (enExample) |
| IL (1) | IL290965B2 (enExample) |
| LT (1) | LT4021901T (enExample) |
| MX (1) | MX2022002271A (enExample) |
| PE (1) | PE20220712A1 (enExample) |
| PL (1) | PL4021901T3 (enExample) |
| PT (1) | PT4021901T (enExample) |
| RS (1) | RS67362B1 (enExample) |
| SI (1) | SI4021901T1 (enExample) |
| SM (1) | SMT202500489T1 (enExample) |
| TW (1) | TW202122395A (enExample) |
| WO (1) | WO2021041588A1 (enExample) |
| ZA (1) | ZA202203515B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478621B2 (en) | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021127554A1 (en) * | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| CA3180670A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CA3228862A1 (en) * | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| CN117088874A (zh) * | 2022-05-19 | 2023-11-21 | 轩竹生物科技股份有限公司 | 二酰甘油激酶抑制剂及其用途 |
| WO2023229375A1 (ko) * | 2022-05-25 | 2023-11-30 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
| KR20230164602A (ko) * | 2022-05-25 | 2023-12-04 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| CN117534665A (zh) * | 2022-08-01 | 2024-02-09 | 山东轩竹医药科技有限公司 | 二酰甘油激酶抑制剂 |
| KR20250061756A (ko) * | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| CA2489560A1 (en) | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CA2533626A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| JP2007503388A (ja) | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| AU2008353145B2 (en) | 2008-01-03 | 2013-09-12 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| US9006257B2 (en) | 2012-02-09 | 2015-04-14 | Glenmark Pharmaceuticals S.A. | Bicyclic compounds as mPGES-1 inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| CN109575016B (zh) | 2017-09-28 | 2022-01-04 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
-
2020
- 2020-08-25 AR ARP200102382A patent/AR119821A1/es unknown
- 2020-08-26 TW TW109129047A patent/TW202122395A/zh unknown
- 2020-08-27 CA CA3149594A patent/CA3149594A1/en active Pending
- 2020-08-27 RS RS20251083A patent/RS67362B1/sr unknown
- 2020-08-27 IL IL290965A patent/IL290965B2/en unknown
- 2020-08-27 SM SM20250489T patent/SMT202500489T1/it unknown
- 2020-08-27 ES ES20768221T patent/ES3057035T3/es active Active
- 2020-08-27 PL PL20768221.2T patent/PL4021901T3/pl unknown
- 2020-08-27 AU AU2020336089A patent/AU2020336089C1/en active Active
- 2020-08-27 WO PCT/US2020/048070 patent/WO2021041588A1/en not_active Ceased
- 2020-08-27 SI SI202030674T patent/SI4021901T1/sl unknown
- 2020-08-27 US US17/004,058 patent/US11584747B2/en active Active
- 2020-08-27 FI FIEP20768221.2T patent/FI4021901T3/fi active
- 2020-08-27 EP EP20768221.2A patent/EP4021901B1/en active Active
- 2020-08-27 PT PT207682212T patent/PT4021901T/pt unknown
- 2020-08-27 JP JP2022513203A patent/JP7650864B2/ja active Active
- 2020-08-27 CN CN202080060991.6A patent/CN114302884B/zh active Active
- 2020-08-27 HR HRP20251203TT patent/HRP20251203T1/hr unknown
- 2020-08-27 BR BR112022001862A patent/BR112022001862A2/pt unknown
- 2020-08-27 DK DK20768221.2T patent/DK4021901T3/da active
- 2020-08-27 MX MX2022002271A patent/MX2022002271A/es unknown
- 2020-08-27 KR KR1020227009618A patent/KR102980691B1/ko active Active
- 2020-08-27 PE PE2022000339A patent/PE20220712A1/es unknown
- 2020-08-27 LT LTEPPCT/US2020/048070T patent/LT4021901T/lt unknown
-
2022
- 2022-02-28 CL CL2022000485A patent/CL2022000485A1/es unknown
- 2022-02-28 CO CONC2022/0002424A patent/CO2022002424A2/es unknown
- 2022-03-25 ZA ZA2022/03515A patent/ZA202203515B/en unknown
- 2022-11-08 US US17/983,097 patent/US20230151007A1/en not_active Abandoned
-
2024
- 2024-08-14 US US18/804,699 patent/US20240400563A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4021901B1 (en) | Substituted pyridopyrimidinonyl compounds useful as t cell activators | |
| KR102767739B1 (ko) | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 | |
| JP7712274B2 (ja) | Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体 | |
| KR102808367B1 (ko) | Hpk1 억제제로서 유용한 이소푸라논 화합물 | |
| ES3008848T3 (en) | Substituted bicyclic piperidine derivatives useful as t cell activators | |
| EP4081516B1 (en) | Substituted quinazolinyl compounds useful as t cell activators | |
| RS64285B1 (sr) | Jedinjenja naftiridinona korisna kao aktivatori t ćelija | |
| EP4568950A1 (en) | Substituted tetrazolyl compounds useful as t cell activators | |
| KR20250046310A (ko) | T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물 | |
| EA043061B1 (ru) | Замещенные нафтиридиноновые соединения, полезные в качестве активаторов т-клеток |